Objective To observe the clinical efficacy and safety of voriconazole in sequential treatment of invasive pulmonary aspergillosis so as to provide guidance for clinical treatment. Methods A total of 192 patients with invasive pulmonary aspergillosis from January 2014 to June 2017 were enrolled in the study and randomly divided into two groups. The control group(n=96) was treated with conventional intravenous administration of voriconqzole, while the observation group (n=96) was given the intravenous sequential oral administration of voriconazole. The improvement of symptoms,clinical efficacy, and adverse reactions were evaluated. The statistical analysis was per-formed with the SPSS13.0 software. Results The clinical cure rate was 89.6% in the observation group and 88.5%in the control group, and the total effective rate was 92.7% in the observation group and 93.8% in the control group. The difference in the clinical cure rate,the total effective rate,and improvement of symptoms between the two groups were no significant. The incidence of adverse reactions was 3.1% in the observation group,which was signifi-cantly lower than 14.6% in the control group(P<0.05). Conclusion The intravenous sequential oral administra-tion of voriconazole is an highly effective and safe administration approach for the patients with invasive pulmonary as-pergillosis,and it can reduce the incidence of adverse reaction.%目的 探讨伏立康唑序贯治疗侵袭性肺曲霉病的临床疗效及安全性,为改进临床治疗提供依据.方法 选择2014年1月-2017年6月收治的侵袭性肺曲霉病患者192例,随机分为两组,其中对照组96例,按常规伏立康唑静脉治疗;观察组96例,给予伏立康唑静脉序贯口服治疗,对两组患者的临床疗效及不良反应进行观察比较.采用 SPSS 13.0软件进行分析.结果 观察组临床治愈率及总有效率分别为89.6%及92.7%,对照组分别为88.5%及93.8%,两组临床治愈率及总有效率差异无统计学意义.观察组不良反应发生率3.1%,明显低于对照组14.6%,差异有统计学意义(P<0.05).结论 伏立康唑静脉序贯口服给药治疗对侵袭性肺曲霉病的疗效良好,且降低了不良反应.
展开▼
